Endonovo Therapeutics Inc (ENDV) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access ENDV Annual Balance Sheets →
Balance sheet data covering Endonovo Therapeutics Inc–Sep 30 2022 offers a view into how Sep 30 2023's financial position has changed alongside business activity.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2023)
(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Assets
Cash & cash equivalent0.00
Cash & Short-term Investments0.00
Accounts receivable0.00
Prepaid Expense And Other Assets Current0.04
Total Current Assets0.04
Intangible Assets0.78
Other Assets, Noncurrent0.00
Total Assets0.82
Liabilities
Accounts Payable and Accrued Liabilities, Current LI1.18
Interest Payable, Current IN0.00
Derivative Liability, Current DE5.90
Notes Payable, Current NO6.95
Other Liabilities, Current5.43
Deferred Compensation Liability, Current LI4.23
Total Current Liabilities23.70
Total Long-term Debt0.00
Other liabilities, Noncurrent0.08
Total Liabilities23.78
Stockholders' Equity
Common Stock Value0.03
Additional Paid In Capital Common Stock43.64
Retained Earnings / Accumulated Deficit-66.63
Other Equity0.00
Common Stockholder's Equity-22.96
Preferred Stockholder's Equity0.00
Total Stockholder's Equity-22.96
Liabilities & Stockholder's Equity0.82
4 historic quarters locked

Sign in to unlock the full Endonovo Therapeutics Inc balance sheet history.

About Endonovo Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001493152-23-046561

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.